Actively Recruiting
Vitamin D for Acute Intracerebral Hemorrhage
Led by The University of Hong Kong · Updated on 2026-05-06
40
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects. VICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.
CONDITIONS
Official Title
Vitamin D for Acute Intracerebral Hemorrhage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of spontaneous intracerebral hemorrhage (ICH)
- Age 18 years or older
- Within 96 hours of ICH onset
- Premorbid Modified Rankin Scale score of 2 or less
- Supratentorial (above the tentorium) ICH location
- Hematoma volume of 2 mL or more
You will not qualify if you...
- Expected life expectancy less than 1 year
- Glasgow Coma Scale score less than 9
- Planned surgical removal of hematoma
- Unable to participate in follow-up activities
- Hypercalcemia (high blood calcium levels)
- Hyperphosphatemia (high blood phosphate levels)
- History of kidney stones
- Bleeding tendency
- Severe kidney impairment
- Severe liver impairment
- Known allergy or contraindication to vitamin D
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
K
Kay Cheong Teo, MBBS, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here